|     OMB                APPROVAL                   OMB Number: 3235-0416                   Expires:                 March 31, 2007                   Estimated average burden                   Hours per response . . . .                182 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**FORM      10-QSB**

**000-50212**

**AIDA      PHARMACEUTICALS, INC.**

| **Nevada**                                                                    |   | **81-0592184**                                      |
|-------------------------------------------------------------------------------|--------|-----------------------------------------------------|
| (State                or other jurisdiction of incorporation or organization) |   | (I.R.S.                Employer Identification No.) |

| **31                Dingjiang Road, Jianggan District, Hangzhou,                China** |   | **310016**                |
|----------------------------------------------------------------------------------------------|--------|---------------------------|
| (Address                of principal executive offices)                                      |   | (Zip                Code) |

**86-0571-85802712**

**APPLICABLE      ONLY TO ISSUERS INVOLVED IN BANKRUPTCY**

**PROCEEDINGS      DURING THE PRECEDING FIVE YEARS**

**APPLICABLE      ONLY TO CORPORATE ISSUES**

**Persons      who are to respond to the collection of information contained in this form      are**
**not      required to respond unless the form displays a currently valid OMB control      **
**number.**

----

|                   |                                                                                                                                                                                    | Page  |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| PART                I. | Financial                Information                                                                                                                                                    | 3     |
|                   |                                                                                                                                                                                    |       |
|                   | Item 1.  Unaudited              Financial Statements                                                                                                                               |       |
|                   |                                                                                                                                                                                    |       |
|                   | Condensed              Consolidated              Balance Sheets as of March 31, 2006 (Unaudited) and December 31,              2005                                                     | 4     |
|                   |                                                                                                                                                                                    |       |
|                   | Condensed              Consolidated              Statements of Income and Comprehensive Income for the Three Months              Ended              March 31, 2006 and 2005 (Unaudited) | 5     |
|                   |                                                                                                                                                                                    |       |
|                   | Condensed              Consolidated Statements of Cash Flows for the Three Months Ended March              31,              2006 and 2005 (Unaudited)                                   | 6     |
|                   |                                                                                                                                                                                    |       |
|                   | Notes to Condensed              Consolidated Financial Statements as of March 31, 2006              (Unaudited)                                                                         | 8     |
|                   |                                                                                                                                                                                    |       |
|                   | Item 2.               Management’s Discussion and Analysis of Financial Condition or Plan              of Operation                                                          | 20    |
|                   |                                                                                                                                                                                    |       |
|                   | Item              3.  Controls and Procedures                                                                                                                                      | 31    |
|                   |                                                                                                                                                                                    |       |
| PART              II.  | Other              Information                                                                                                                                                          | 31    |
|                   |                                                                                                                                                                                    |       |
|                   | Item 1. Legal              Proceedings                                                                                                                                                  | 31    |
|                   |                                                                                                                                                                                    |       |
|                   | Item 4. Submission              of              Matters to a Vote of Security Holders                                                                                                   | 31    |
|                   |                                                                                                                                                                                    |       |
|                   | Item              6.  Exhibits and Reports on Form 8-K                                                                                                                             | 32    |
|                   |                                                                                                                                                                                    |       |
|                   | Signatures                                                                                                                                                                              | 32    |

----

**PART      I - FINANCIAL INFORMATION**

**Item      1. Financial Statements (unaudited)**

----

**AIDA      PHARMACEUTICAL, INC. **

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**CONDENSED      CONSOLIDATED BALANCE SHEETS **

|  **ASSETS**                                                                                                                   |   |
|------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                               |   | March                31, 2006(Unaudited) |   | December                31, 2005 |   |
| **CURRENT                ASSETS**                                                                                                  |   |   |   |   |   |   |   |
|                Cash and cash equivalents                                                                                      |   | $ | 2,277,406 |   | $ | 3,129,450 |   |
|                  Restricted cash                                                                                              |   |   | 1,768,886 |   |   | 1,903,487 |   |
|                Accounts receivable, net of allowance for doubtful accounts of $386,688              and $386,688         |   |   |   |   |   |   |   |
|                    as of March 31, 2006 and December 31, 2005, respectively                                         |   |   | 8,949,963 |   |   | 9,390,137 |   |
|                  Notes receivable                                                                                             |   |   | 3,219,062 |   |   | 3,323,076 |   |
|                  Inventories                                                                                                  |   |   | 4,355,390 |   |   | 3,348,592 |   |
|                  Due from related parties                                                                                     |   |   | 67,361 |   |   | 54,120 |   |
|                  Other receivables, prepaid expenses, and other assets                                                        |   |   | 403,831 |   |   | 449,672 |   |
|                  Due from employees                                                                                           |   |   | 705,698 |   |   | 497,486 |   |
|                  Prepayments for goods                                                                                        |   |   | 547,678 |   |   | 316,960 |   |
|                     Total current assets                                                                       |   |   | 22,295,275 |   |   | 22,412,980 |   |
|                                                                                                                               |   |   |   |   |   |   |   |
|                  Plant and equipment, net                                                                                     |   |   | 11,860,934 |   |   | 11,987,572 |   |
|                  Land use rights, net                                                                                         |   |   | 2,150,555 |   |   | 1,755,440 |   |
|                  Construction in progress                                                                                     |   |   | 867,762 |   |   | 856,776 |   |
|                  Patents, net                                                                                                 |   |   | 1,965,819 |   |   | 1,788,014 |   |
|                Due from employees                                                                                             |   |   | 587,548 |   |   | 616,440 |   |
|                  Long term investments                                                                                        |   |   | 218,605 |   |   | 218,605 |   |
|                  Deposits                                                                                                     |   |   | 2,761,137 |   |   | 2,817,391 |   |
|                  Deferred taxes                                                                                               |   |   | 237,763 |   |   | 205,919 |   |
|                                                                                                                               |   |   |   |   |   |   |   |
|     **TOTAL                ASSETS**                                                                            |   | $ | 42,945,398 |   | $ | 42,659,137 |   |
|                                                                                                                               |   |   |   |   |   |   |   |
| **LIABILITIES                AND SHAREHOLDERS’ EQUITY**                                                                      |
| **CURRENT                LIABILITIES**                                                                                             |   |   |   |   |   |   |   |
|                  Accounts payable                                                                                             |   | $ | 3,300,560 |   | $ | 1,622,449 |   |
|   Other                payables and accrued liabilities                                                                  |   |   | 2,501,213 |   |   | 3,003,233 |   |
|                  Short term debt                                                                                              |   |   | 18,757,785 |   |   | 21,450,710 |   |
|                  Due to related parties                                                                                       |   |   | 123,005 |   |   | 159,492 |   |
|                  Taxes payable                                                                                                |   |   | 72,012 |   |   | 38,722 |   |
|                  Customer deposits                                                                                            |   |   | 1,180,803 |   |   | 1,390,526 |   |
|                Due to employees                                                                                               |   |   | 117,928 |   |   | 493,492 |   |
|                  Deferred taxes                                                                                               |   |   | 121,438 |   |   | 106,279 |   |
|                     Total current liabilities                                                                  |   |   | 26,174,744 |   |   | 28,264,903 |   |
|                                                                                                                               |   |   |   |   |   |   |   |
| **LONG-TERM                LIABILITIES**                                                                                           |   |   |   |   |   |   |   |
|                  Long-term bank loan                                                                                          |   |   | 3,742,048 |   |   | 3,717,380 |   |
|                  Deferred taxes                                                                                               |   |   | 470,007 |   |   | 387,316 |   |
|                  Notes payable                                                                                                |   |   | 2,120,494 |   |   | - |   |
|                  Minority interests                                                                                           |   |   | 3,632,229 |   |   | 3,565,431 |   |
|                     Total long-term liabilities                                                                |   |   | 9,964,778 |   |   | 7,670,127 |   |
|                                                                                                                                    |   |   |   |   |   |   |   |
| **TOTAL                LIABILITIES**                                                                                               |   |   | 36,139,522 |   |   | 35,935,030 |   |
|                                                                                                                               |   |   |   |   |   |   |   |
| **SHAREHOLDERS’                EQUITY**                                                                                      |   |   |   |   |   |   |   |
|                Common stock, $0.006 par value; 75,000,000 shares authorized; 25,000,000              shares                   |   |   |   |   |   |   |   |
|                    issued and outstanding at March 31, 2006 and December 31, 2005,                respectively      |   |   | 150,000 |   |   | 150,000 |   |
|                  Additional paid-in capital                                                                                   |   |   | 3,293,323 |   |   | 3,293,323 |   |
|                Retained earnings (the restricted portion is $593,971 and $593,971              at              March 31, 2006 |   |   |   |   |   |   |   |
|                    and December 31, 2005, respectively)                                                             |   |   | 3,151,031 |   |   | 3,136,495 |   |
|                  Accumulated other comprehensive income                                                                       |   |   | 211,522 |   |   | 144,289 |   |
| Total                Shareholders’ Equity                                                                                    |   |   | 6,805,876 |   |   | 6,724,107 |   |
|                                                                                                                                    |   |   |   |   |   |   |   |
| **TOTAL                LIABILITIES AND SHAREHOLDERS’ EQUITY**                                                                |   | $ | 42,945,398 |   | $ | 42,659,137 |   |

----

**AIDA      PHARMACEUTICALS, INC. **

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES **

**CONDENSED      CONSOLIDATED STATEMENTS**

**OF      INCOME AND COMPREHENSIVE INCOME**

|                                                                                                                                  |   | **THREE                  MONTHS ENDED MARCH 31,** |       |
|---------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------|------------|
|                                                                                                                                  |   | **2006**                                          |       | **2005** |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **REVENUES**                                                                                                                          |   |                                              | 5,331,827  |   |   | 4,800,613 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **COST                  OF GOODS SOLD**                                                                                               |   |                                              | (2,983,114 | ) |   | (1,435,860 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **GROSS                  PROFIT**                                                                                                     |   |                                              | 2,348,713  |   |   | 3,364,753 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| Selling                and distribution                                                                                               |   |                                              | (1,680,669 | ) |   | (1,542,479 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| General                  and administrative                                                                                           |   |                                              | (647,210   | ) |   | (546,684 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| Research                  and development                                                                                             |   |                                              | (1,600     | ) |   | (120,823 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **INCOME                  FROM OPERATIONS**                                                                                           |   |                                              |       |   |   |   |   |
|                                                                                                                                  |   |                                              | 19,234     |   |   | 1,154,767 |   |
| **OTHER                  INCOME (EXPENSES)**                                                                                          |   |                                              |       |   |   |   |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
|                     Interest expense, net                                                                                   |   |                                              | (269,605   | ) |   | (213,979 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
|                     Government grants                                                                                       |   |                                              | 459,993    |   |   | - |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
|                     Gain on nonmonetary transaction                                                                         |   |                                              | -          |   |   | 125,097 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
|                     Other (loss) income, net                                                                                |   |                                              | (31,145    | ) |   | 68,240 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **INCOME****FROM OPERATIONS****BEFORE INCOME                  TAXES**                                                                 |   |                                              | 178,477    |   |   | 1,134,125 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **INCOME                  TAXES**                                                                                                     |   |                                              | (97,143    | ) |   | (11,402 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **INCOME                  FROM CONTINUING OPERATIONS BEFORE MINORITY                  INTERESTS**                                     |   |                                              | 81,334     |   |   | 1,122,723 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **MINORITY                  INTERESTS**                                                                                               |   |                                              | (66,798    | ) |   | (375,997 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **INCOME                  FROM CONTINUING OPERATIONS**                                                                                |   |                                              | 14,536     |   |   | 746,726 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **DISCONTINUED                  OPERATION**                                                                                           |   |                                              |       |   |   |   |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| Gain                  from disposition of discontinued operation                                                                      |   |                                              | -          |   |   | 26,068 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| Income                  from discontinued operation                                                                                   |   |                                              | -          |   |   | 161,341 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **GAIN                  FROM DISCONTINUED OPERATION**                                                                                 |   |                                              | -          |   |   | 187,409 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **NET                  INCOME**                                                                                                       |   |                                              | 14,536     |   |   | 934,135 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **OTHER                  COMPREHENSIVE INCOME (LOSS)**                                                                                |   |                                              |       |   |   |   |   |
| Foreign                  currency translation gain (loss)                                                                             |   |                                              | 67,233     |   |   | (2,296 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **OTHER                  COMPREHENSIVE INCOME (LOSS) BEFORE INCOME TAXES**                                                            |   |                                              | 67,233     |   |   | (2,296 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **INCOME                  TAXES RELATED TO OTHER COMPREHENSIVE INCOME**                                                               |   |                                              | (23,532    | ) |   | - |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **OTHER                  COMPREHENSIVE INCOME (LOSS), NET OF INCOME TAXES**                                                           |   |                                              | 43,701     |   |   | (2,296 | ) |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **COMPREHENSIVE                  INCOME**                                                                                             |   | $                                                 | 58,237     |   | $ | 931,839 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| **WEIGHTED                  AVERAGE SHARES OUTSTANDING BASIC AND DILUTED**                                                            |   |                                              | 25,000,000 |   |   | 23,375,000 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| Income                  per common share from continuing operations, basic and                  diluted                               |   | $                                                 | 0.00       |   | $ | 0.03 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| Income                  per common share from gain from disposition of discontinued operation,                  basic and diluted     |   | $                                                 | 0.00       |   | $ | 0.01 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| Income                  per common share from income from discontinued operation, basic                  and                  diluted |   | $                                                 | 0.00       |   | $ | 0.00 |   |
|                                                                                                                                  |   |                                              |       |   |   |   |   |
| Net                  income per common share, basic and diluted                                                                       |   | $                                                 | 0.00       |   | $ | 0.04 |   |

----

**AIDA      PHARMACEUTICALS, INC. **

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES **

**CONDENSED      CONSOLIDATED STATEMENTS OF CASH FLOWS**

|                                                                                                                  |   |                  **For the Three Months Ended March 31,** |       |
|-----------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------|------------|
|                                                                                                                  |   | **2006**                                                       |       | **2005** |   |
| **CASH                FLOWS FROM OPERATING ACTIVITIES:**                                                              |   |                                                           |       |   |   |   |   |
|                  Net income                                                                                      |   | $                                                              | 14,536     |   | $ | 934,135 |   |
|                  Adjustments to reconcile net income to net cash provided byoperating                activities: |   |                                                           |       |   |   |   |   |
|                  Depreciation and amortization                                                                   |   |                                                           | 385,226    |   |   | 352,571 |   |
|                  Deferred taxes                                                                                  |   |                                                           | 65,091     |   |   | (286,817 | ) |
|                  Gain on nonmonetary transaction                                                                 |   |                                                           | -          |   |   | (125,097 | ) |
|                  Minority interests’ share of net income                                                   |   |                                                           | 66,798     |   |   | 375,997 |   |
|                  Gain on disposal of discontinued operation                                                      |   |                                                           | -          |   |   | (26,068 | ) |
|                                                                                                                  |   |                                                           |       |   |   |   |   |
| **Changes                in operating assets and liabilities, net of effects of                acquisition:**         |   |                                                           |       |   |   |   |   |
|                                                                                                                  |   |                                                           |       |   |   |   |   |
| **(Increase)                Decrease In:**                                                                            |   |                                                           |       |   |   |   |   |
|                  Accounts receivable                                                                             |   |                                                           | 440,175    |   |   | 8,103 |   |
|                  Inventories                                                                                     |   |                                                           | (1,006,797 | ) |   | 950,319 |   |
|                  Other receivables, prepaid expenses, and other assets                                           |   |                                                           | 46,757     |   |   | 294,113 |   |
|                  Prepayments for goods                                                                           |   |                                                           | (230,718   | ) |   | 484,545 |   |
|                  Discontinued operation                                                                          |   |                                                           | -          |   |   | 423,351 |   |
|                                                                                                                  |   |                                                           |       |   |   |   |   |
| **Increase                (Decrease) In:**                                                                            |   |                                                           |       |   |   |   |   |
|                  Accounts payable                                                                                |   |                                                           | 1,678,111  |   |   | (1,230,830 | ) |
|                  Other payables and accrued liabilities                                                          |   |                                                           | (502,025   | ) |   | 2,810,937 |   |
|                  Due to employees                                                                                |   |                                                           | (375,564   | ) |   | 54,813 |   |
|                  Taxes payable                                                                                   |   |                                                           | 33,291     |   |   | 57,977 |   |
|                  Customer deposits                                                                               |   |                                                           | (209,723   | ) |   | 577,821 |   |
|                  Discontinued operation                                                                          |   |                                                           | -          |   |   | 876,051 |   |
| Net                cash provided by operating activities                                                              |   |                                                           | 405,158    |   |   | 6,531,921 |   |
|                                                                                                                  |   |                                                           |       |   |   |   |   |
| **CASH                FLOWS FROM INVESTING ACTIVITIES:**                                                              |   |                                                           |       |   |   |   |   |
|                  Restricted cash                                                                                 |   |                                                           | 134,601    |   |   | (2,667,432 | ) |
|                  Purchases of plant and equipment                                                                |   |                                                           | (201,395   | ) |   | (175,886 | ) |
|                  Purchases of construction in progress                                                           |   |                                                           | (10,987    | ) |   |   |   |
|                  Proceeds from disposal of discontinued operation, net of cash                sold               |   |                                                           | -          |   |   | 1,581,755 |   |
|                  Purchase of land use right                                                                      |   |                                                           | (393,117   | ) |   | - |   |
|                  Deposit for long term investment                                                                |   |                                                           | (124,211   | ) |   | - |   |
|                  Deposit for fixed assets                                                                        |   |                                                           | (56,531    | ) |   | - |   |
|                  Notes receivable                                                                                |   |                                                           | 104,014    |   |   | (354,775 | ) |
|                  Due from related parties                                                                        |   |                                                           | (13,240    | ) |   | - |   |
|                  Due from employees                                                                              |   |                                                           | (179,320   | ) |   | (904,810 | ) |
|                  Purchase of a subsidiary, net of cash acquired                                                  |   |                                                           | -          |   |   | (936,707 | ) |
|                  Discontinued operation                                                                          |   |                                                           | -          |   |   | 224,141 |   |
| Net                cash used in investing activities                                                                  |   |                                                           | (740,186   | ) |   | (3,233,714 | ) |
|                                                                                                                  |   |                                                           |       |   |   |   |   |
| **CASH                FLOWS FROM FINANCING ACTIVITIES:**                                                              |   |                                                           |       |   |   |   |   |
|                  Repayments of short-term debt                                                                   |   |                                                           | (2,692,925 | ) |   | (228,927 | ) |
|                  Proceeds from/(repayments of) notes payable                                                     |   |                                                           | 2,120,494  |   |   | (631,815 | ) |
|                  Proceeds from related parties                                                                   |   |                                                           | -          |   |   | 246,553 |   |
|                  Repayment to related parties                                                                    |   |                                                           | (36,486    | ) |   | (1,348,910 | ) |
|                  Discontinued operation                                                                          |   |                                                           | -          |   |   | (1,666,084 | ) |
| Net                cash used in financing activities                                                                  |   |                                                           | (608,917   | ) |   | (3,629,183 | ) |
|                                                                                                                  |   |                                                           |       |   |   |   |   |
| **DECREASE                IN CASH AND CASH EQUIVALENTS**                                                              |   |                                                           | (943,945   | ) |   | (330,976 | ) |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**CONDENSED      CONSOLIDATED STATEMENTS OF CASH FLOWS**

|                                                                   |   |                  **For the Three Months Ended March 31,** |      |
|------------------------------------------------------------------------|--------|----------------------------------------------------------------|-----------|
|                                                                   |   | **2006**                                                       |      | **2005** |   |
|                                                                   |   |                                                           |      |   |   |   |   |
|                  Effect of exchange rate changes on cash          |   |                                                           | 91,901    |   |   | (2,296 | ) |
|                  Cash and cash equivalents at beginning of period |   |                                                           | 3,129,450 |   |   | 2,810,050 |   |
|                                                                   |   |                                                           |      |   |   |   |   |
| **CASH                AND CASH EQUIVALENTS AT END OF PERIOD**          |   | $                                                              | 2,277,406 |   | $ | 2,476,778 |   |
|                                                                   |   |                                                           |      |   |   |   |   |
| **SUPPLEMENTARY                CASH FLOW INFORMATION**                 |   |                                                           |      |   |   |   |   |
|                  Income taxes paid                                |   | $                                                              | (6,296    | ) | $ | (912 | ) |
|                  Interest paid                                    |   | $                                                              | (261,327  | ) | $ | (203,689 | ) |

**    SUPPLEMENTAL      NON-CASH      DISCLOSURES:**

|  1. |  During              the three months ended March 31, 2006, a liability of $639,230 was              settled              by transferring equipment with a net book value of $514,133 resulting              in a              $125,097 gain.                                                                                                                                                                                                                                                |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|  2. |  During              the three months ended March 31, 2006, $274,229 was transferred from              deposits to patents.                                                                                                                                                                                                                                                                                                                                                                  |
|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|  3. |  On                February 1, 2005, the Company purchased an additional 52% interest                in                Changzhou Fangyuan Pharmaceutical Co., Ltd. for $3,232,542. Thereafter,                Changzhou Fangyuan  Pharmaceutical                Co., Ltd. became a 66% owned subsidiary of the Company. The following                represents the assets purchased and liabilities assumed at                the acquisition                date: |

|                    Land use right, net                                                         |   | $      | 1,182,180   |   |
|---------------------------------------------------------------------------------------------------------------|--------|--------|-------------|--------|
|                    Patents, net                                                                |   |   | 1,868,534   |   |
|                    Construction in progress                                                    |   |   | 856,776     |   |
|                    Deposits                                                                    |   |   | 1,603,483   |   |
|                    Plant and equipment, net                                                    |   |   | 8,354,078   |   |
|                    Cash and cash equivalents                                                   |   |   | 2,295,835   |   |
|                    Accounts receivable, net                                                    |   |   | 1,038,479   |   |
|                    Inventories, net                                                            |   |   | 467,223     |   |
|                    Other receivables and prepayments                                           |   |   | 122,748     |   |
|                    Prepayments for goods                                                       |   |   | 380,554     |   |
|                    Due from related parties                                                    |   |   | 1,917,521   |   |
| Total                assets purchased                                                                         |   | $      | 20,087,411  |   |
|                                                                                                          |   |   |        |   |
|                    Short term bank loans                                                       |   |   | (8,667,193  | )      |
|                    Accounts payable                                                            |   |   | (370,371    | )      |
|                    Accrued expense                                                             |   |   | (459,159    | )      |
|                    Other payable and accrued liabilities                                       |   |   | (1,007,904  | )      |
|                    Customer deposits                                                           |   |   | (112,373    | )      |
|                    Deferred taxes                                                              |   |   | (216,278    | )      |
|                    Long-term bank loans                                                        |   |   | (3,717,380  | )      |
| Total                liabilities assumed                                                                      |   | $      | (14,550,658 | )      |
|                                                                                                          |   |   |        |   |
| Total                net assets                                                                               |   | $      | 5,536,753   |   |
|                                                                                                          |   |   |        |   |
| Share                percentage                                                                               |   |   | 66          | %      |
|                                                                                                          |   |   |        |   |
| Net                assets acquired                                                                            |   | $      | 3,654,257   |   |
|                                                                                                          |   |   |        |   |
| Total                consideration paid (including the investments of $421,715 in prior                years) |   | $      | 3,654,257   |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**1.**
**ORGANIZATION      AND PRINCIPAL ACTIVITIES**

| (1)   | Effective                November 30, 2005, the Company implemented a 1 for 6.433138 reverse                stock                split prior to the closing of the agreement so that the Company’s                10,453,850 outstanding shares as of the date of the agreement then                represent 1,625,000 shares of common stock; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | The                Company issued and delivered to the shareholders of Earjoy an aggregate                of                23,375,000 shares of its post-reverse stock split common stock,                representing 93.5% of all of the Company’s issued and outstanding common                stock, in exchange for 100% of the outstanding capital of Earjoy; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**1.    **
**ORGANIZATION      AND PRINCIPAL ACTIVITIES (CONTINUED)**

**2.     **BASIS      OF PRESENTATION****

**3.    PRINCIPLES      OF      CONSOLIDATION**

**4.    **CONCENTRATIONS****

|                               |   | **Sales**                                                                            |                                                                           | **Accounts                Receivable** |
|------------------------------------|--------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------|
| **Major                Customers** |   | **For                the Three Months Ended ****March                31, 2006** | **For                the Three Months Ended****March                31, 2005** |                                   | **March                31,****2006** | **December                31,****2005** |
| Company                A           |   | 2%                                                                                   | 1%                                                                             |                                   | 3% | 4% |
| Company                B           |   | 10%                                                                                  | 3%                                                                             |                                   | 3% | 11% |
| Company                C           |   | 10%                                                                                  | 1%                                                                             |                                   | 11% | 4% |
| Company                D           |   | 21%                                                                                  | 12%                                                                            |                                   | 7% | 7% |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**4.    CONCENTRATIONS      (CONTINUED)**

|                               |   | **Purchase**                                                 |                                                         | **Accounts                Payable** |
|------------------------------------|--------|--------------------------------------------------------------|--------------------------------------------------------------|-------------------------------------|
| **Major                Suppliers** |   | **For                the Three Months Ended March 31, 2006** | **For                the Three Months Ended March 31, 2005** |                                | **March                31,****2006** | **December                31,****2005** |
| Company                E           |   | 12%                                                          | 12%                                                          |                                | 12% | 11% |
| Company                F           |   | 8%                                                           | 7%                                                           |                                | 3% | 4% |

**5.    USE      OF      ESTIMATES**

**6.     FOREIGN      CURRENCY TRANSLATION**

|                                                 | **March                31, 2006** |   | **December                31, 2005** |
|------------------------------------------------------|-----------------------------------|--------|--------------------------------------|
| Period                end RMB: US$ exchange rate     | 8.0170                            |   | 8.0702                               |
| Average                yearly RMB: US$ exchange rate | 8.0436                            |   | 8.1734                               |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**7.**
**   FAIR      VALUE OF FINANCIAL      INSTRUMENTS**

**8.             EARNINGS PER SHARE**

**9.             **
**NOTES      RECEIVABLE**

| Bank                  acceptance notes                  : |   |    |                                                                  |   |    |
|-----------------------------------------------------------|--------|---------|-----------------------------------------------------------------------|--------|---------|
|                                                 |   |    | **March                  31, 2006****(Unaudited)**               |   |    | **December                  31, 2005** |   |
| Due                  February 4, 2006                     |   |  $ | -                                                                     |   |  $ | 8,674 |   |
| Due                  February 15, 2006                    |   |    | -                                                                     |   |    | 136,864 |   |
| Due                  March 11, 2006                       |   |    | -                                                                     |   |    | 6,196 |   |
| Due                  April 13, 2006                       |   |    | -                                                                     |   |         | 49,566 |   |
| Subtotal                                                  |   |  $ | -                                                                     |   |  $ | 201,300 |   |
|                                                      |   |    |                                                                  |   |    |   |   |
| Notes                  receivable from related companies: |   |    |                                                                  |   |    |   |   |
|                                                      |   |    | **March                  31,                  2006(Unaudited)**  |   |    | **December                  31, 2005**  |   |
| Due                  November 11, 2006                    |   |  $ | 374,205                                                               |   |  $ | 371,738 |   |
| Due                  November 30, 2006                    |   |    | 62,367                                                                |   |    | 61,956 |   |
| Due                  December 2, 2006                     |   |    | 124,735                                                               |   |    | 123,913 |   |
| Due                  October 14, 2006                     |   |    | 343,528                                                               |   |    | 319,951 |   |
| Subtotal                                                  |   |  $ | 904,835                                                               |   |  $ | 877,558 |   |
|                                                      |   |    |                                                                  |   |    |   |   |

| Notes                  receivable from unrelated companies: |   |    |                                                         |   |    |
|-------------------------------------------------------------|--------|---------|--------------------------------------------------------------|--------|---------|
|                                                   |   |    | **March                  31, 2006******(Unaudited)****  |   |    | **December                  31, 2005** |   |
| Due                  May 20, 2006                           |   |  $ | 124,735                                                      |   |  $ | 123,913 |   |
| Due                  December 1, 2006                       |   |    | 1,167,966                                                    |   |    | 1,160,265 |   |
| Due                  December 31, 2006                      |   |    | 1,021,526                                                    |   |    | 960,040 |   |
| Subtotal                                                    |   |    | 2,314,227                                                    |   |    | 2,244,218 |   |
|                                                        |   |    |                                                         |   |    |   |   |
| Total                                                       |   | $       | 3,219,062                                                    |   | $       | 3,323,076 |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**10.**
**INVENTORIES**

|                                |   | **March                31, 2006****(Unaudited)**  |      | **December**** 31,                2005** |   |
|-------------------------------------|--------|--------------------------------------------------------|-----------|-----------------------------------------------|--------|
| Raw                materials        |   | $                                                      | 1,028,342 |                                          | $      | 735,017 |   |
| Work-in-progress                    |   |                                                   | 672,403   |                                          |   | 357,220 |   |
| Finished                goods       |   |                                                   | 2,530,257 |                                          |   | 1,788,025 |   |
| Processing                materials |   |                                                   | 124,388   |                                          |   | 468,330 |   |
|                                |   | $                                                      | 4,355,390 |                                          | $      | 3,348,592 |   |

**11.**
**DUE      TO/FROM RELATED PARTIES**

|                                                      |   | **March                31, 2006****(Unaudited)** |   | **December****31,                2005** |   |
|-----------------------------------------------------------|--------|--------------------------------------------------|--------|-----------------------------------------|--------|
| Current:                                                  |   |                                             |   |                                    |   |   |   |
| Ningbo                Tianheng Pharmaceuticals Co., Ltd.  |   | $                                                | 12,473 |                                    | $      | 12,391 |   |
| Zhejiang                Guobang Veterinary Drug Co., Ltd. |   |                                             | 54,888 |                                    |   | 41,729 |   |
| Total                due from related parties             |   | $                                                | 67,361 |                                    | $      | 54,120 |   |

|                                                      |   | **March                31, 2006****(Unaudited)** |    | **December**** ****31,                2005** |   |
|-----------------------------------------------------------|--------|--------------------------------------------------|---------|---------------------------------------------------|--------|
| Merlin                Green Canada Inc.                   |   | $                                                | 26,360  |                                              | $      | 136,593 |   |
| Jin’ou                Group                         |   |                                             | 23,051  |                                              |   | 22,899 |   |
| Zhejiang                Guobang Veterinary Drug Co., Ltd. |   |                                             | 73,594  |                                              |   | - |   |
| Total                due to related parties               |   | $                                                | 123,005 |                                              | $      | 159,492 |   |

|                                    |   | **March                31, 2006****(Unaudited)** |          | **December** **31,                2005** |   |
|-----------------------------------------|--------|--------------------------------------------------|---------------|-----------------------------------------------|--------|
| Current                                 |   | $                                                | 705,698  |                                          | $      | 497,486  |   |
| Long-term                               |   |                                             | 587,548       |                                          |   | 616,440 |   |
| Total                due from employees |   | $                                                | 1,293,246     |                                          | $      | 1,113,926 |   |

|                                  |   | **March                31, 2006****(Unaudited)** |    | **December****31,                2005** |   |
|---------------------------------------|--------|--------------------------------------------------|---------|-----------------------------------------|--------|
| Current                               |   | $                                                | 117,928 |                                    | $      | 493,492 |   |
| Total                due to employees |   | $                                                | 117,928 |                                    | $      | 493,492 |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**12.     BUSINESS      COMBINATION**

| Total                consideration paid (including previous investment) | $      | 3,654,257    |
|-------------------------------------------------------------------------|--------|--------------|
| Fair                value of assets acquired                            |   | (18,309,680) |
| Fair                value of liabilities assumed                        |   | 9,603,434    |
| Negative                goodwill                                        |   | (5,051,989)  |
|                                                                    |   |         |
| Negative                goodwill applied to a patent                    |   | 5,051,989    |
| Total                                                                   | $      | 5,051,989    |

| Net                income                              | $      | 932,110 |
|--------------------------------------------------------|--------|---------|
|                                                   |   |    |
| Net                income per share, basic and diluted | $      | 0.04    |

**13.**
**PLANT      AND EQUIPMENT**

|                                                |   | **March                31, 2006****(Unaudited)** |       | **December                31, 2005** |   |
|-----------------------------------------------------|--------|--------------------------------------------------|------------|--------------------------------------|--------|
| At                cost:                             |   |                                             |       |                                 |   |   |   |
|                  Buildings                     |   | $                                                | 7,005,014  |                                 | $      | 6,944,082 |   |
|                  Machinery                     |   |                                             | 7,947,663  |                                 |   | 7,832,139 |   |
|                  Motor vehicles                |   |                                             | 611,682    |                                 |   | 607,649 |   |
|                  Office equipment              |   |                                             | 591,697    |                                 |   | 573,220 |   |
|                  Leasehold improvements        |   |                                             | 368,453    |                                 |   | 366,024 |   |
|                                                |   |                                             | 16,524,509 |                                 |   | 16,323,114 |   |
|  Less:                Accumulated depreciation |   |                                             |       |                                 |   |   |   |
|                  Buildings                     |   |                                             | 1,146,174  |                                 |   | 1,089,490 |   |
|                  Machinery                     |   |                                             | 2,787,383  |                                 |   | 2,582,907 |   |
|                  Motor vehicles                |   |                                             | 355,267    |                                 |   | 332,125 |   |
|                  Office equipment              |   |                                             | 320,299    |                                 |   | 293,561 |   |
|                  Leasehold improvements        |   |                                             | 54,452     |                                 |   | 37,459 |   |
|                                                |   |                                             | 4,663,575  |                                 |   | 4,335,542 |   |
| Plant                and equipment, net             |   | $                                                | 11,860,934 |                                 | $      | 11,987,572 |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**13.**
**PLANT      AND EQUIPMENT (CONTINUED)**

**14.     LAND      USE      RIGHTS**

|                                          |   | **March                31, 2006****(Unaudited)** |      |  **December                31, 2005** |   |
|-----------------------------------------------|--------|--------------------------------------------------|-----------|--------------------------------------------|--------|
| Cost                                          |   | $                                                | 2,301,792 |                                       | $      | 1,896,092 |   |
| Less:                Accumulated amortization |   |                                             | 151,237   |                                       |   | 140,652 |   |
| Land                use rights, net           |   | $                                                | 2,150,555 |                                       | $      | 1,755,440 |   |

| 2006                within one year |   | $      | 35,522    |   |
|-------------------------------------|--------|--------|-----------|--------|
| 2007                                |   |   | 47,362    |   |
| 2008                                |   |   | 47,362    |   |
| 2009                                |   |   | 47,362    |   |
| 2010                                |   |   | 47,362    |   |
| Thereafter                          |   |   | 1,925,585 |   |
| Total                               |   | $      | 2,150,555 |   |

**15.**
**PATENT**

|                                          |   | **March                31, 2006****(Unaudited)** |      |  **December                31, 2005** |   |
|-----------------------------------------------|--------|--------------------------------------------------|-----------|--------------------------------------------|--------|
| Cost                                          |   | $                                                | 2,468,307 |                                       | $      | 2,194,078 |   |
| Less:                Accumulated amortization |   |                                             | 502,488   |                                       |   | 406,064 |   |
| Patents,                net                   |   | $                                                | 1,965,819 |                                       | $      | 1,788,014 |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**15.**
**PATENT      (CONTINUED)**

| 2006                within one year |   | $      | 331,104   |   |
|-------------------------------------|--------|--------|-----------|--------|
| 2007                                |   |   | 331,104   |   |
| 2008                                |   |   | 275,830   |   |
| 2009                                |   |   | 275,606   |   |
| 2010                                |   |   | 225,712   |   |
| Thereafter                          |   |   | 526,463   |   |
| Total                               |   | $      | 1,965,819 |   |

**16.**
**DEPOSITS**

|                                              |   | **March****31,                  2006****(Unaudited)** |      |  **December**** 31,                  2005** |   |
|---------------------------------------------------|--------|-------------------------------------------------------|-----------|-------------------------------------------------------|--------|
| Deposits                  for patent              |   | $                                                     | 623,051   |                                                  | $      | 910,138 |   |
| Deposits                  for plant and equipment |   |                                                  | 1,106,827 |                                                  |   | 1,003,930 |   |
| Deposits                  for land use right      |   |                                                  | 341,999   |                                                  |   | 341,999 |   |
| Deposits                  for acquisition         |   |                                                  | 689,260   |                                                  |   | 561,324 |   |
| Total                                             |   | $                                                     | 2,761,137 |                                                  | $      | 2,817,391 |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**17.**
**LONG-TERM      INVESTMENTS**

|                                                       |   | **Ownership****Interest** |   | **March****31,                2006****(Unaudited)** |   | **Ownership****Interest** |   | **December**** 31,                2005** |   |
|------------------------------------------------------------|--------|---------------------------|--------|-----------------------------------------------------|--------|---------------------------|--------|-----------------------------------------------|--------|
| At                cost:                                    |   |                      |   |                                                |   |                      |   |                                          |   |   |   |   |   |
| Hangzhou                Longde Medical Machinery Co., Ltd. |   |                      | 10.6%  |                                                | $      | 97,790                    |   |                                          | 10.6%  |   | $ | 97,790 |   |
| Zhejiang                Anglikang Pharmaceutical Co., Ltd. |   |                      | 4.25%  |                                                |   | 120,815                   |   |                                          | 4.25%  |   |   | 120,815 |   |
|                                                       |   |                      |   |                                                | $      | 218,605                   |   |                                          |   |   | $ | 218,605 |   |

**18.**
**SHORT-TERM      DEBT**

|                                                                                                                                                                                                                                                                                                                                  |   | **March****31,                2006****(Unaudited)** |      | **December****31,                2005** |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------|-----------|-----------------------------------------|--------|
| Loan                from Industrial and Commercial Bank of China Qingchun Branch, due                July 24,                2006, monthly interest only payments at 5.115% per annum, secured                by                assets owned by the Company.                                                                          |   | $                                                   | 743,476   |                                    | $      | 743,476 |   |
|                                                                                                                                                                                                                                                                                                                                  |   |                                                |      |                                    |   |   |   |
| Loan                from Industrial and Commercial Bank of China Qingchun Branch, due                August                1, 2006, monthly interest only payments at 5.115% per annum, secured                by                assets owned by the Company.                                                                         |   |                                                | 867,389   |                                    |   | 867,389 |   |
|                                                                                                                                                                                                                                                                                                                                  |   |                                                |      |                                    |   |   |   |
| Loan                from Industrial and Commercial Bank of China Qingchun Branch, due                August                8, 2006, monthly interest only payments at 5.115% per annum, secured                by                assets owned by the Company.                                                                         |   |                                                | 774,454   |                                    |   | 774,454 |   |
|                                                                                                                                                                                                                                                                                                                                  |   |                                                |      |                                    |   |   |   |
| Loan                from Industrial and Commercial Bank of China Qingchun Branch, due                August                21, 2006, monthly interest only payments at 5.115% per annum, secured                by                assets owned by the Company.                                                                        |   |                                                | 623,675   |                                    |   | 619,563 |   |
|                                                                                                                                                                                                                                                                                                                                  |   |                                                |      |                                    |   |   |   |
| Loan                from Hangzhou Commercial Bank Gaoxin Branch due April 25, 2006, monthly                interest only payments at 5.115% per annum, guaranteed by Hangzhou                Jinou                Group and Xinchang Guobang Chemicals Co., Ltd.. (subsequently repaid                on                its due date) |   |                                                | 1,239,127 |                                    |   | 1,239,127 |   |
|                                                                                                                                                                                                                                                                                                                                  |   |                                                |      |                                    |   |   |   |
| Loan                from Bank of China Kaiyuan Branch due April 17, 2006, monthly interest                only payments at 5.58% per annum, guaranteed by Xinchang Guobang                Chemicals                Co., Ltd. And Qiu Jiajun & Jin Biao (subsequently repaid on its due                date)                       |   |                                                | 1,239,127 |                                    |   | 1,239,127 |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**18.**
**SHORT-TERM      DEBT (CONTINUED)**

| Loan                from Industrial Bank due September 26, 2006, monthly interest only                payments at 5.115% per annum, respectively, guaranteed by Jin’ou Group                                                                                                                                                  |   |   | 1,239,127  |   |   | 1,239,127  |   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|------------|--------|--------|------------|--------|
|                                                                                                                                                                                                                                                                                                                                |   |   |       |   |   |       |   |
| Loan                from Industrial and Commercial Bank of China, due April 10, 2006                monthly                interest only payments at 4.575% per annum, secured by assets owned                by the                Company. (subsequently repaid on its due date)                                                  |   |   | 1,115,214  |   |   | 1,115,214  |   |
|                                                                                                                                                                                                                                                                                                                                |   |   |       |   |   |       |   |
| Loan                from China Development Bank Haikou Branch, due November 24, 2006,                monthly                interest only payments at 5.115% per annum, guaranteed by Haikou                Assure                Investment Ltd.                                                                                   |   |   | 347,259    |   |   | 371,738    |   |
|                                                                                                                                                                                                                                                                                                                                |   |   |       |   |   |       |   |
| Loan                from China Citic Bank Hangzhou Branch, due January 1, 2006, monthly                interest only payments at 4.785% per annum, guaranteed by Xinchang                Guobang                Chemicals Co., Ltd. (subsequently repaid on its due date)                                                           |   |   | -          |   |   | 619,563    |   |
|                                                                                                                                                                                                                                                                                                                                |   |   |       |   |   |       |   |
| Loan                from Changzhou Commercial Bank, due February 15, 2006, monthly interest                only payments at 6.51% per annum, guaranteed by Changzhou High-tech                Development Co. Ltd. (subsequently repaid on its due date)                                                                            |   |   | -          |   |   | 619,563    |   |
|                                                                                                                                                                                                                                                                                                                                |   |   |       |   |   |       |   |
| Loan                from Huaxia Bank Wenhui Branch due March 16, 2006, monthly interest                only                payments at 4.8825% per annum, guaranteed by Xinchang Guobang Chemicals                Co., Ltd. and Ningbo Tianheng Pharm. Co. Ltd. (subsequently repaid                on its                due date) |   |   | -          |   |   | 743,476    |   |
|                                                                                                                                                                                                                                                                                                                                |   |   |       |   |   |       |   |
| Loan                from China Citic Bank Hangzhou Branch, due January 22, 2006, monthly                interest only payments at 4.785% per annum, guaranteed by Xinchang                Guobang                Chemicals Co., Ltd. (subsequently repaid on its due date)                                                          |   |   | -          |   |   | 495,651    |   |
|                                                                                                                                                                                                                                                                                                                                |   |   |       |   |   |       |   |
| Loans                from Changzhou Commercial Bank, due April 15, 2006 and January 21,                2006,                respectively, monthly interest only payments at 6.975% per annum,                guaranteed by Changzhou High-tech Development Co. Ltd.                                                                 |   |   | 3,118,373  |   |   | 3,097,817  |   |
| Total                short-term bank loans                                                                                                                                                                                                                                                                                          |   |   | 11,307,221 |   |   | 13,785,285 |   |

| Notes                payable to unrelated companies: |   | **March** **31,                2006****(Unaudited)** |          | **December**** 31,                2005** |   |
|------------------------------------------------------|--------|-----------------------------------------------------------|---------------|-----------------------------------------------|--------|
|                   Due January 4, 2006      |   |                                                      | -             |                                          |   | 146,261 |   |
|                   Due April 5, 2006        |   |                                                      | 311,837       |                                          |   | 309,781 |   |
|                 Due April 20, 2006         |   |                                                      | 311,837  |                                          |   | 309,781  |   |
|                   Due April 29, 2006       |   |                                                      | 748,410       |                                          |   | 743,476 |   |
|                   Due May 1, 2006          |   |                                                      | 1,247,349     |                                          |   | 1,239,127 |   |
|                   Due May 9, 2006          |   |                                                      | 147,332       |                                          |   | 146,361 |   |
|                   Due May 25, 2006         |   |                                                      | 1,247,349     |                                          |   | 1,239,127 |   |
|                   Due August 31, 2006      |   |                                                      | 1,372,085     |                                          |   | 1,363,039 |   |
|                   Due November 30, 2006    |   |                                                      | 2,064,365     |                                          |   | 2,168,472 |   |
| Total                notes payable                   |   |                                                      | 7,450,564     |                                          |   | 7,665,425 |   |
| Total                short-term debt                 |   | $                                                         | 18,757,785    |                                          | $      | 21,450,710 |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**19.**
**NOTES      PAYABLE**

|                                                                                                                                                                                                                                           |   |  **March****31,                2006****(Unaudited)** |      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------|-----------|
|  Due              February 20, 2009, at 1% per annum, unsecured                                                                                                                                                                           |   |  $                                                   | 1,247,349 |   |
|                                                                                                                                                                                                                                           |   |                                                      |      |   |
|  Due                December 31, 2009, monthly interest only payments at 6.03% per                                  annum, guaranteed by Changzhou Donghong Bio-Pharmaceutical                   Technology Co., Ltd. |   |                                                      | 873,145   |   |
|  Total                                                                                                                                                                                                                                    |   |  $                                                   | 2,120,494 |   |

**20. **
**DISCONTINUED      OPERATION**

|                                      |   | **For                the Three**** Months                Ended****March                31, 2005****(Unaudited)** |       |
|-------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------|------------|
| Revenue                                   |   | $                                                                                                                     | 3,776,980  |   |
| Cost                of goods sold         |   |                                                                                                                  | (3,544,336 | ) |
| Gross                profit               |   |                                                                                                                  | 232,644    |   |
| Selling                and distribution   |   |                                                                                                                  | (37,254    | ) |
| General                and administrative |   |                                                                                                                  | (26,679    | ) |
| Interest                expense           |   |                                                                                                                  | (7,370     | ) |
| Income                tax expense         |   |                                                                                                                  | -          |   |
| Net                income                 |   | $                                                                                                                     | 161,341    |   |

----

**AIDA      PHARMACEUTICALS, INC.**

**(FORMERLY      BAS CONSULTING, INC.) AND SUBSIDIARIES**

**NOTES      TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR      THE THREES MONTHS ENDED MARCH 31, 2006 AND 2005**

**20. **
**    DISCONTINUED      OPERATION (CONTINUED)**

|                                                          |   |   | **March                31, 2005 (date of disposal)****(Unaudited)**  |   |
|---------------------------------------------------------------|--------|--------|---------------------------------------------------------------------------|--------|
| Cash                and cash equivalents                      |   | $      | 21,778                                                                    |   |
| Other                current assets                           |   |   | 3,601,410                                                                 |   |
| Non-current                assets                             |   |   | 1,245,583                                                                 |   |
| Current                liabilities                            |   |   | (4,668,677                                                                | )      |
| Total                net assets of the discontinued operation |   | $      | 200,094                                                                   |   |

**21.**
**COMMITMENTS      AND CONTINGENCIES**

| Period                Ending March 31 |   | **Amount** |    |
|---------------------------------------|--------|------------|---------|
| 2006                                  |   |       | 89,723  |   |
| 2007                                  |   |       | 69,854  |   |
| 2008                                  |   |       | 69,854  |   |
| 2009                                  |   |       | 69,854  |   |
| 2010                                  |   |       | 69,854  |   |
| Thereafter                            |   |       | 110,601 |   |
| Total                                 |   | $          | 479,740 |   |

| Period                Ending March 31, |   |   | **Amount** |   |
|----------------------------------------|--------|--------|------------|--------|
| 2006                                   |   | $      | 979,201    |   |

**22.    LEGAL      PROCEEDING**

----

**Item      2. Management’s Discussion and Analysis or Plan of      Operation.**

**FORWARD-LOOKING      STATEMENTS**

**GENERAL**

**OUR      BUSINESS**

| a)   | Earjoy                Group Limited, (“Earjoy”) |
|----------------|-------------------------------------------------------------|

| b)   | Hangzhou                Aida Pharmaceutical Co., Ltd (“Hangzhou                Aida”); |
|----------------|----------------------------------------------------------------------------------------------------|

| c)   | Hangzhou                Boda Medical Research and Development Co., Ltd.                (“Boda”); |
|----------------|--------------------------------------------------------------------------------------------------------------|

| d)   | Hainan                Aike Pharmaceutical Co., Ltd. (“Aike”)                and; |
|----------------|----------------------------------------------------------------------------------------------|

| e)   | Changzhou                Fangyuan Pharmaceutical Co., Ltd.                (“Fangyuan”) |
|----------------|----------------------------------------------------------------------------------------------------|

----

**Products**

| **Product**                                      | **Produced                By** | **Specification**                      | **Standard/Category**              |
|--------------------------------------------------|--------------------------------|----------------------------------------|------------------------------------|
| Etimicin                Sulfate Injection Powder | Aida                           | 50mg,                100mg, 150mg      | National                Category-A |
| Etimicin                Sulfate Injection liquid | Fangyuan                       | 1ml,                2ml                | National                Category-A |
| Etimicin                Sulfate for transfusion  | Aike                           | 100ml(with                100mg/200mg) | National                Category-D |

----

**Etimicin      Sulfate**

|   | (i) | respiratory                infection, such as acute bronchitis, acute onset of chronic bronchitis                and                pulmonary infections; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | kidney                and urinogenital infection, such as acute pyelonephritis or acute                onset of                chronic cystitis; |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | soft                skin tissue infection; and |
|--------|-------|------------------------------------------------|

|   | (iv) | trauma                and operations (before and after) preventive uses. |
|--------|------|--------------------------------------------------------------------------|

**Products      Under Development**

| Ø   | **5-Deoxy-Fluorordine.**Aida                has developed a new liquid for injection type of drug generated from                5-fluroruacil that has displayed better anticancer results and fewer                side                effects. This new product has been under clinical testing since 1998.                Test                results showed that it has only nominal side effects, a broad spectrum                and                is highly effective. The Company has applied for production approval                of                5-deoxy-fluororidine for injection from State Food and Drug Administration                in the PRC. This new drug will have a 6-year protection period once                the                approval is obtained. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|

| Ø   | **Apoptotic                Factor (rh-Apo2l).**                Rh-Apo2l is                being evaluated in a Phase I trial as a potential cancer therapeutic.                The                Phase I clinical trials are expected to be completed at the end of                April                2006. Shanghai Qiaer Bio-Technology, which is acquired by Hangzhou                Aida,                has applied for three patents from the Chinese government authority.                One                patent has been granted and the other two are currently in process.                We                plans to complete the second and third stage clinical trials in the                second                half of 2007 and get production approval in the second half of                2008. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Ø   | **Methylcanthatidinimide                For Injection.**It                is another new drug being developed by Fangyuan used for cancer treatment.                It will be a Category B new drug. The clinical tests are expected                to be                completed by the first half of 2008 and the production is expected                to                begin by the end of 2009. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Ø   | **SYO2.**                Hangzhou Aida has created one medicine extracted from herbal essence,                called SYO2 that has exhibited bioactivity for brain anti-thrombosis.                The                drug, developed solely by an aligned research center of Hangzhou                Aida, has                shown to be safe, effective and without side effects. It is believed                that                stroke patients treated by SYO2 would be fully recovered after                administration of the drug. Aida has completed SYO2’s pharmacological                study and has applied for a patent. The Company plans to apply for                clinical tests within the next 18 months. Hangzhou Aida intends to                apply                for production approval by the end of 2010. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Ø   | The                demand for international quality drugs by the Chinese populace has                historically increased as per capita income and the standard of living                increase continually; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Ø   | The                sale of Hangzhou Aida’s Etimicin sulfate is estimated to grow continuously                for the next three years after several years of market                development; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Ø   | Aida                is now planning to build up international business relationship with                global players gradually in future. The international markets should                increase the sales growth; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Ø   | Aida                has achieved a monopoly status in this industry, with all types of                Etimicin products and from the material chain to the final product                chain.                This is a significant and unique advantage of Aida                and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Industry      Regulation**

**Good      Manufacturing Practices (GMP)**

**Research      and Development**

----

**Manufacturing**

|   | a) | adequacy                of raw materials, supplies and packaging materials; |
|--------|----|-----------------------------------------------------------------------------|

|   | b) | efficiency                each individual production process; and |
|--------|----|-------------------------------------------------------------------|

|   | c) | physical                conditions of equipment, parts and                consumables. |
|--------|----|----------------------------------------------------------------------------------------|

**Intellectual      Property and Trademarks**

----

**Competition**

**Price:**

**Quality:**

**Promotion:**

**Customers**

**Facilities**

**Existing      Production Facilities **

| 1. | Hangzhou Aida Pharmaceutical Co., Ltd.              Constructed according to national Good Manufacturing Practice (“GMP”)              standards, this plant occupies an area of approximately 17,330 square              meters and has an annual production capacity of approximately 15 million              powder doses, 150 million capsules and 200 million              tablets. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 2. | Changzhou Fangyuan Pharmaceutical Co., Ltd.              Constructed according to national Good Manufacturing Practice (“GMP”)              standards, this plant occupies an area of approximately 80,000 square              meters and has an annual production capacity of approximately 7.5 million              liquid doses and 3200 kilograms of Etimicin base.  |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 3. | Hainan                Aike Pharmaceutical Co., Ltd.                Constructed according to national Good Manufacturing Practice (“GMP”)                standards, this plant occupies an area of approximately 3,900 square                meters and has an annual production capacity of approximately 12                million                bottles of transfusion                preparations. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Employees**

*Labor      Agreement Regulation of People’s Republic of China*

**CRITICAL      ACCOUNTING POLICIES AND ESTIMATES **

| 1. | Persuasive evidence of an arrangement exists; |
|----|-----------------------------------------------|
|   |   |
|--------|--------|
| 2. | Delivery has occurred or services have been rendered; |
|----|-------------------------------------------------------|
|   |   |
|--------|--------|
| 3. | The seller's price to the buyer is fixed or determinable;                and |
|----|------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 4. | Collectibility is reasonably assured. |
|----|---------------------------------------|

----

**RESULTS      OF OPERATIONS - THREE MONTHS ENDED MARCH 31, 2006 AS COMPARED TO THREE MONTHS      ENDED MARCH 31, 2005**

|                                            |   | Three                months Ended March 31, |   |
|-------------------------------------------------|--------|---------------------------------------------|--------|
|                                            |   | 2006                                        |   | 2005 |   |
| Revenues                                        |   |                                        | 100.00 | % |   | 100.00 | % |
| Cost                of goods sold               |   |                                        | (55.95 | )% |   | (29.91 | )% |
| Gross                margin                     |   |                                        | 44.05  | % |   | 70.09 | % |
| Research                and development         |   |                                        | (0.03  | )% |   | (2.52 | )% |
| Selling                and distribution         |   |                                        | (31.52 | )% |   | (32.13 | )% |
| General                and administrative       |   |                                        | (12.14 | )% |   | (11.39 | )% |
| Other                income (expense)           |   |                                        | 2.98   | % |   | (0.42 | )% |
| Income                taxes                     |   |                                        | (1.82  | )% |   | (0.24 | )% |
| Minority                interests               |   |                                        | (1.25  | )% |   | (7.83 | )% |
| Gain                from discontinued operation |   |                                        | 0.00   | % |   | 3.90 | % |
| Net                income                       |   |                                        | 0.27   | % |   | 19.46 | % |

**Revenues,      Cost of Goods Sold and Gross Profit **

|                                                                                                                                                               |   |   Three                months ended March 31, |      |       |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------|-----------|------------|--------|
|  Companies                                                                                                                                                    |   |  2006                                              |      |  2005 |   | Increase/(Decrease) |   |
| Hangzhou                Aida PharmaceuticalCo.,                Ltd (“Hangzhou Aida”) specializesin                the production of Etimicinpowder     |   | $                                                       | 1,332,506 |       | $      | 2,521,965 |   | $ | (1,189,459 | ) |
|                                                                                                                                                               |   |                                                    |      |       |   |   |   |   |   |   |
| Hainan                Aike pharmaceuticalCo.,                Ltd (“Aike”) specializesin                the production of Etimicintransfusion           |   |                                                    | 3,063,184 |       |   | 1,774,131 |   |   | 1,289,053 |   |
|                                                                                                                                                               |   |                                                    |      |       |   |   |   |   |   |   |
| Hangzhou                Boda Medical Research and Development Co., Ltd.(“Boda”)                                                                        |   |                                                    | -         |       |   | - |   |   | - |   |
|                                                                                                                                                               |   |                                                    |      |       |   |   |   |   |   |   |
| Changzhou                Fangyuan Pharmaceutical Co.,Ltd.                (“Fangyuan”) specializesin                the production of Etimicininjection |   |                                                    | 936,137   |       |   | 504,517 |   |   | 431,620 |   |
|                                                                                                                                                               |   |                                                    |      |       |   |   |   |   |   |   |
| TOTAL                                                                                                                                                              |   | $                                                       | 5,331,827 |       | $      | 4,800,613 |   | $ | 531,214 |   |

----

|                                                                                                                                              |   |   Three                months ended March 31, |      |       |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------|-----------|------------|--------|
|  Companies                                                                                                                                   |   |  2006                                              |      |  2005 |   | Increase/(Decrease) |   |
| Hangzhou                Aida Pharmaceutical Co. Ltd (“Hangzhou Aida”) specializes in the                production of Etimicin powder |   | $                                                       | 382,950   |       | $      | 589,861 |   | $ | (206,911 | ) |
|                                                                                                                                              |   |                                                    |      |       |   |   |   |   |   |   |
| Hainan                Aike pharmaceuticalCo. Ltd (“Aike”) specializesin the production of                Etimicintransfusion          |   |                                                    | 1,785,339 |       |   | 755,558 |   |   | 1,029,781 |   |
|                                                                                                                                              |   |                                                    |      |       |   |   |   |   |   |   |
| Hangzhou                Boda Medical Research and Development Co., (“Boda”)                                                           |   |                                                    | -         |       |   | - |   |   | - |   |
|                                                                                                                                              |   |                                                    |      |       |   |   |   |   |   |   |
| Changzhou                Fangyuan PharmaceuticalLtd.                (“Fangyuan”) specializesin the production of Etimicininjection    |   |                                                    | 814,825   |       |   | 90,441 |   |   | 724,384 |   |
|                                                                                                                                              |   |                                                    |      |       |   |   |   |   |   |   |
| TOTAL                                                                                                                                             |   | $                                                       | 2,983,114 |       | $      | 1,435,860 |   | $ | 1,547,254 |   |

**Research      and Developments**

----

**S**
**elling      and Distribution**

|                                       |   | Three                months ended March                31,  |      |       |   |
|--------------------------------------------|--------|------------------------------------------------------------------|-----------|------------|--------|
|  Breakdown                of Expenses |   |  2006                                                       |      |  2005 |   | Increase/(Decrease) |   |
| Traveling                expenses          |   | $                                                                | 487,849   |       |   | 401,564 |   | $ | 86,285 |   |
| Sale                commissions            |   |                                                             | 217,376   |       |   | 287,026 |   |   | (69,650 | ) |
| Office                expenses             |   |                                                             | 224,165   |       |   | 211,471 |   |   | 12,694 |   |
| Payroll                                    |   |                                                             | 94,424    |       |   | 77,312 |   |   | 17,112 |   |
| Conference                fees             |   |                                                             | 69,188    |       |   | 117,325 |   |   | (48,137 | ) |
| Rent                                       |   |                                                             | 68,136    |       |   | 27,173 |   |   | 40,963 |   |
| Entertainment                              |   |                                                             | 53,087    |       |   | 52,887 |   |   | 200 |   |
| Other                expenses              |   |                                                             | 220,208   |       |   | 219,038 |   |   | 1,170 |   |
| Advertising                expenses        |   |                                                             | 246,236   |       |   | 148,683 |   |   | 97,553 |   |
|                                       |   |                                                             |      |       |   |   |   |   |  |   |
| TOTAL                                      |   | $                                                                | 1,680,669 |       | $      | 1,542,479 |   | $ | 138,190 |   |

**General      and Administrative **

|                                       |   |  Three                months ended March 31, |    |       |   |
|--------------------------------------------|--------|---------------------------------------------------|---------|------------|--------|
|  Breakdown                of Expenses |   |  2006                                        |    |  2005 |   | Increase/(Decrease) |   |
| Traveling                expenses          |   | $                                                 | 63,216  |       |   | 47,108 |   | $ | 16,108 |   |
| Office                expenses             |   |                                              | 27,660  |       |   | 41,073 |   |   | (13,413 | ) |
| Payroll                                    |   |                                              | 117,810 |       |   | 109,254 |   |   | 8,556 |   |
| Conference                fees             |   |                                              | 0       |       |   | 6,797 |   |   | (6,797 | ) |
| Rent                                       |   |                                              | 448     |       |   | 5,595 |   |   | (5,147 | ) |
| Consultancy                fees            |   |                                              | 77,407  |       |   | 12,177 |   |   | 65,230 |   |
| Entertainment                              |   |                                              | 36,287  |       |   | 22,955 |   |   | 13,332 |   |
| Other                expenses              |   |                                              | 137,628 |       |   | 186,306 |   |   | (48,678 | ) |
| Depreciation                               |   |                                              | 151,884 |       |   | 75,487 |   |   | 76,397 |   |
| Social              compensation           |   |                                              | 34,870  |       |   | 39,932 |   |   | (5,062 |  ) |
|                                       |   |                                              |         |       |   |  |   |   |  |   |
| TOTAL                                      |   | $                                                 | 647,210 |       | $      | 546,684 |   | $ | 100,526 |   |

----

**Other        Income (Expenses)**

|                                                        |   |  Three                  months Ended March 31, |     |       |   |
|-------------------------------------------------------------|--------|-----------------------------------------------------|----------|------------|--------|
|  Breakdown                  of other income/(expenses) |   |  2006                                          |     |  2005 |   | Increase/(Decrease) |   |
| Interest                  expense, net                      |   | $                                                   | (269,605 | )          | $      | (213,979 | ) | $ | (55,626 | ) |
| Government                  grants                          |   |                                                | 459,993  |       |   | - |   |   | 459,993 |   |
| Gain                  from nonmonetary transaction          |   |                                                | -        |       |   | 125,097 |   |   | (125,097 | ) |
| Other                  (expense) income, net                |   |                                                | (31,145  | )          |   | 68,240 |   |   | (99,385 | ) |
|                                                        |   |                                                |     |       |   |   |   |   |   |   |
| TOTAL                                                       |   | $                                                   | 159,243  |       | $      | (20,642 | ) | $ | 179,885 |   |

**Income        Taxes **

**Net      Income **

**LIQUIDITY      AND CAPITAL RESOURCES **

**Cash        **

----

**Working        Capital **

**Code        of Ethics**

**Item      3. Controls and Procedures.**

**PART      II - OTHER INFORMATION**

**tem      1. Legal Proceedings.**

**Item      4. Submission of Matters to a Vote of Security Holders.**

----

**Item        6. Exhibits and Reports on Form 8-K.**

**Reports        on Form 8-K **

|  **Date**            |  **Form** |  **Items                Reported**                          |
|---------------------------|----------------|------------------------------------------------------------------|
|  1-11-06   |  8-K/A    |  2.01,                3.02, 5.01, 5.02, 5.03, 5.06 and 9.01 |
|                      |           |                                                             |
|  2-2-06    |  8-K      |  4.01 and 9.01                                              |
|                      |           |                                                             |
|  2-27-06             |  8-K      |  5.02                                                       |
|                      |           |                                                             |
|  3-7-06              |  8-K      |  5.02 and 9.01                                              |
|                      |           |                                                             |
|  4-14-06             |  8-K      |  2.02 and                9.01                               |

**Exhibits      **

|  **Exhibit No.** |  **Title of              Document**                                                                                                                                                          |     **Location** |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
|  31.1            |  Certification of the Principal              Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act              of              2002                                           |     Attached     |
|                  |                                                                                                                                                                                                   |                            |
|  31.2            |  Certification of the Principal              Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act              of              2002                                           |     Attached     |
|                  |                                                                                                                                                                                                   |                            |
|  32.1            |  Certification of the Principal Executive Officer                pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906                 of the Sarbanes-Oxley Act of 2002*  |     Attached     |
|                  |                                                                                                                                                                                                   |                            |
|  32.2            |  Certification of the Principal Financial Officer                pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906                 of the Sarbanes-Oxley Act of 2002*  |     Attached     |

***      **

**SIGNATURES**

**AIDA      PHARMACEUTICALS, INC.**

|  Date: May, 2006  |                           |   |
|------------------------|--------------------------------|--------|
|                   |                           |   |
|                   |  /s/ Biao Jin             |   |
|                   |  Mr. Biao Jin             |   |
|                   |  Chief Executive Officer  |   |
|                   |                           |   |
|                   |                           |   |
|  Date: May , 2006 |                           |   |
|                   |                           |   |
|                   |  /s/ Hui Lin              |   |
|                   |  Ms.              Hui Lin |   |
|                   |  Chief Financial Officer  |   |

----